ME-344

News alerts, weekly reports and conference planners

Company:

Ligand, MEI

Drug class:

mTOR inhibitor, Mitochondrial OXHPHOS inhibitor

Related drugs:

›

HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	bevacizumab + ME-344 Sensitive: C3 – Early Trials bevacizumab + ME-344 Sensitive : C3	bevacizumab + ME-344 Sensitive: C3 – Early Trials bevacizumab + ME-344 Sensitive : C3
MCL1 overexpression	Acute Myelogenous Leukemia	MCL1 overexpression	Acute Myelogenous Leukemia	ME-344 Sensitive: D – Preclinical ME-344 Sensitive : D	ME-344 Sensitive: D – Preclinical ME-344 Sensitive : D

Associations
(2)